Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Cases of SLE Skin Disease
Description
The presentation discusses challenging cases of skin disease related to systemic lupus erythematosus (SLE), emphasizing the various manifestations and treatment approaches. One case detailed a 39-year-old female with SLE experiencing deep finger ulcers, attributed to vasculitis, and treated using a combination of vasodilators and botulinum toxin, leading to successful healing. Another case involved a 28-year-old male suffering from recurrent angioedema linked to his high disease activity, which responded poorly to typical treatments but improved significantly with bradykinin-targeting therapies after reclassifying his condition. A notable case of a 13-year-old female with a blistering eruption was presented; although initially diagnosed with linear IgA bullous dermatosis, her workup revealed features consistent with active SLE and lupus nephritis. The significance of understanding the underlying mechanisms of symptoms such as angioedema and blistering eruptions was highlighted, and medical strategies tailored to the pathophysiology were emphasized for effective treatment. The cases collectively underscore the complexity of SLE and the need for careful diagnostic consideration and targeted therapy.
View moreConclusions
- Finger ulcers in SLE can have various underlying causes, and vascular-targeted therapy can be beneficial for treatment.
- Botulinum toxin is particularly effective for treating finger ulcers in SLE patients.
- Neutrophilic dermatosis in SLE presents with papules and plaques that typically last 24-48 hours, and can be effectively treated with Anifrolumab.
- Patients with angioedema related to SLE may require high doses of prednisone for relief, and understanding the underlying mechanism helps direct appropriate therapy.
- Acquired angioedema in SLE patients can lead to complement consumption and requires specific treatments targeting bradykinin.
- Recognition of the mechanism behind angioedema is critical for effective management, with different treatments for histaminergic and bradykinin-induced types.
- Bullous lupus can present as a de novo condition in patients and should be differentiated from linear IgA bullous dermatosis through histologic and immunologic evaluation.
- Xu et al ., JAMA Dermatology, 2023
- Gusdorf et al ., Medicine (Baltimore), 2014
- Larson and Granter, Hum. Pathol ., 2014
- Cugno et al ., Autoimmunity Reviews, 2008
- Cozzani et al ., Acta Derm Venereol ., 2020
- Murugesu and Tirumalae, Am J Dermatopathol ., 2024
- Genovese et al ., Orphanet J Rare Dis, 2019
- de Risi-Pugliese et al ., Semin Arthritis Rheum, 2018
- Chanprapaph et al ., Lupus, 2017